Journal
NATURE REVIEWS DRUG DISCOVERY
Volume 12, Issue 11, Pages 847-865Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nrd4140
Keywords
-
Funding
- University of Texas MD Anderson Research Trust
- University of Texas System Regents Research Scholar
- CLL Global Research Foundation
- US National Institutes of Health (NIH)/US National Cancer Institute (NCI) [CA135444]
- US Department of Defense Breast Cancer Idea Award
- Developmental Research Awards in breast cancer, ovarian cancer, brain cancer, prostate cancer, multiple myeloma and leukaemia [P50 CA100632]
- Specialized Programs of Research Excellence (SPOREs) [P50 CA097007]
- Sister Institution Network Fund (SINF) grant from the MD Anderson Cancer Center
- German Cancer Research Center (DKFZ) in chronic lymphocytic leukaemia
- SINF grant in colorectal cancer
- Laura and John Arnold Foundation
- RGK Foundation
- Jean Perkins Foundation
- Nautica Malibu Triathlon Funds
- Pablove Foundation
- St. Baldrick's Foundation
- Southern California Clinical and Translational Science Institute
- Funds from the Saban Research Institute
- NCI [P30CA014089]
- Hugh and Audy Lou Colvin Foundation
- T.J. Martell Foundation
Ask authors/readers for more resources
The first cancer-targeted microRNA (miRNA) drug - MRX34, a liposome-based miR-34 mimic - entered Phase I clinical trials in patients with advanced hepatocellular carcinoma in April 2013, and miRNA therapeutics are attracting special attention from both academia and biotechnology companies. Although miRNAs are the most studied non-coding RNAs (ncRNAs) to date, the importance of long non-coding RNAs (lncRNAs) is increasingly being recognized. Here, we summarize the roles of miRNAs and lncRNAs in cancer, with a focus on the recently identified novel mechanisms of action, and discuss the current strategies in designing ncRNA-targeting therapeutics, as well as the associated challenges.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available